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A B S T R A C T   
Conducting randomised clinical trials (RCTs) in idiosyncratic drug-induced liver injury (DILI) is challenging. This 
systematic review aims to summarise the design and findings of RCTs in the prevention and management of 
idiosyncratic DILI. A systematic literature search up to January 31st, 2020 was performed. Recognised scales 
were used to assess methodological bias and quality of the studies. Quantitative and qualitative analyses were 
performed. Heterogeneity was assessed with I2 statistic. Overall, 22 RCTs were included: 12 on prevention (n =
2,471 patients) and 10 in management (n = 797) of DILI/non-acetaminophen DILI-related acute liver failure 
(ALF). Silymarin (eight studies), bicyclol (four), magnesium isoglycyrrhizinate (three), N-acetylcysteine (three), 
tiopronin (one), L-carnitine (one), and traditional Chinese medicines (two) were tested in the intervention arm, 
while control arm mostly received standard supportive care or placebo. Main efficacy criteria in the prevention 
RCTs was DILI incidence or peak of liver enzymes value. In management RCTs, the efficacy parameter was 
usually 50 % decrease or normalisation of liver enzymes, or survival rate in DILI-related ALF patients. Overall, 15 
trials described the randomisation method, eight were double-blind (n = 672) and nine had sample size esti-
mation (n = 880). Four RCTs involving 377 patients used an intention-to-treat analysis. Based on the scarce 
number of trials available, tested agents showed limited efficacy in DILI prevention and management and a 
favourable safety profile. In conclusion, heterogeneity among studies in DILI case qualification and methodologic 
quality was evident, and the RCTs performed demonstrated limited efficacy of specific interventions. Interna-
tional research networks are needed to establish a framework on RCTs design and therapeutic endpoints.   
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1. Introduction 
Idiosyncratic drug-induced liver injury (DILI) is an uncommon but 
potentially severe hepatic disorder presenting with an array of pheno-
types and whose diagnosis is still one of exclusion. Due to the difficulties 
in collecting sizeable and homogenous cohort of patients, DILI remains a 
relatively orphan disorder from a therapeutic standpoint [1]. 
Management of DILI consists of a high level of suspicion and rapid 
discontinuation of the offending drug in combination with supportive 
treatment if necessary [2]. In the majority of DILI cases spontaneous 
recovery follows, but in a fraction of them acute liver failure (ALF) 
requiring liver transplantation or leading to death occurs [3]. Currently, 
no specific therapy has been approved for DILI treatment. Nonetheless, 
some therapeutic approaches, based on anecdotal observations, have 
been tested. Thus, cholestyramine has been tried to treat 
terbinafine-induced hepatotoxicity [4], whilst the use of carnitine has 
been shown in individual cases or case series to improve valproic 
acid-induced liver damage [5]. Similarly, the potential benefit of urso-
deoxycholic acid as hepatoprotective agent for the management of 
pruritus in persistent cholestatic DILI is controversial [6–8]. 
Corticosteroids have long been used empirically in the management 
of some forms of DILI and more recently, with the rationale that adap-
tive immune system is involved in DILI pathogenesis [9]. However, in a 
retrospective analysis including 361 ALF patients, some of whom had 
DILI, treatment with corticosteroids failed to improve overall survival 
[10]. 
A prospective controlled trial conducted in the King’s College Hos-
pital concluded that the administration of N-acetylcysteine (NAC) 
improved survival in patients with fulminant hepatic failure after 
paracetamol overdose [11]. A post hoc analysis of a multicentre pro-
spective study from the Acute Liver Failure Study Group involving 173 
patients with ALF of various aetiologies, including DILI-related ALF, 
showed a beneficial effect of NAC treatment in those with grade I–II 
encephalopathy significantly improved transplant free survival man-
agement of ALF [12]. Conversely, two trials in paediatric population 
reported no efficacy of NAC [13,14]. In a retrospective, uncontrolled 
study the combination of NAC and prednisolone improved liver pa-
rameters in 21 patients with suspected severe DILI related to flupirtine 
[15]. Thus, conflicting results were shown in different, mostly under-
powered studies, and these results await further validation. 
Oxidative stress caused by reactive metabolites from drugs has been 
suggested as a pathological mechanism of liver injury [16–18]. Hence, a 
number of natural components exhibiting antioxidant properties both in 
animal models and in vitro experiments have received growing attention 
in the last years. These include silymarin, a natural compound present in 
species derived from Silybum marianum (commonly known as Milk 
thistle) [19,20]; bicyclol, a novel synthetic anti-hepatitis drug derived 
from diphenyl dimethyl bicarboxylate [21]; or magnesium isoglycyr-
rhizinate (MgIG), the magnesium salt of 18β-glycyrrhizic acid extracted 
from liquorice (a traditional Chinese medicine) [22], which have also 
been considered as a promising approach for further clinical 
development. 
Due to the complexity and low prevalence of idiosyncratic DILI, 
undertaking randomised clinical trials (RCTs) faces multi-layered chal-
lenges. The aim of the current study was to perform a systematic review 
and meta-analysis to summarise the design and findings of RCTs in 
prevention and management of idiosyncratic DILI and non- 
acetaminophen DILI-related ALF. 
2. Material and methods 
2.1. Literature search and study selection 
The protocol for the systematic review and meta-analysis was 
registered in the international prospective register of systematic reviews 
(PROSPERO) with the registration number CRD42020170475. This 
systematic review was performed following the PRISMA guidelines. 
Eligible literature published up to January 31st, 2020 was identified 
through a search in PubMed, MEDLINE, EMBASE, Web of Science, the 
Cochrane Central Register of Controlled Trials (CENTRAL), and an 
additional search of grey literature (proceedings, white papers) in 
OpenGrey database to help minimise publication bias. The search 
strategy comprised the following terms and Boolean operators: “drug- 
induced liver injury” OR “drug-induced hepatotoxicity” OR “acute liver 
failure”, combined with “preven*” OR “manag*” OR “treat*” OR “trial”. 
Two researchers (HN and JSC) led the search, screened the titles and 
abstracts, and evaluated the adequacy of the studies. Any discrepancies 
were solved by consulting a senior researcher (MIL). References cited by 
the included studies and review articles and meta-analysis identified 
throughout the literature search were reviewed to retrieve additional 
studies. 
2.2. Inclusion criteria 
To be included, each study had to meet all of the following criteria: 
1) be an original article; 2) be a RCT conducted in adult and/or paedi-
atric population; 3) describe the use of pharmacological or herbal 
treatment on the prevention or management of idiosyncratic DILI or 
non-acetaminophen DILI-related ALF; 4) explain the methodology of the 
trial, including the inclusion criteria, treatment regimen in the experi-
mental and control arm, and the definition and/or diagnosis of DILI and/ 
or non-acetaminophen DILI-related ALF. Studies on animals or RCTs 
which used experimental treatment or extracorporeal approaches, i.e. 
neither pharmacological nor herbal drugs, and those which did not 
present stratified results for non-acetaminophen DILI-related ALF, were 
excluded. In case we could not retrieve the full text, corresponding au-
thors were contacted and asked for a copy. If our request was not 
answered, the study was excluded. 
2.3. Data extraction 
Data were extracted by two researchers (HN and JSC), and discrep-
ancies resolved through consultation to a third researcher (IAA). The 
following data were extracted from the included studies: surname of the 
first author, year of publication, RCT location, number of patients, 
treatment regimen in the experimental and control arm, primary and 
secondary outcomes, and diagnostic criteria of DILI. In those RCTs 
which provided a registry number, the protocol was consulted to 
retrieve further information. If any data were unclear, authors were 
contacted to obtain further information. 
2.4. Quality assessment 
The Review Manager (RevMan) software version 5.3 (the Cochrane 
Collaboration, 2014, Nordic Cochrane Center, Copenhagen, Denmark) 
was used to evaluate the quality of the included studies in terms of seven 
domains: random sequence generation, allocation concealment, blind-
ing to participants and personnel, blinding to outcome assessment, 
incomplete outcome data, selective reporting, and other biases such as 
baseline imbalance, sample size estimation and use of intention-to-treat 
analysis (ITT) [23,24]. Each domain was judged according to the pres-
ence of high, low, or unclear/unknown risk of bias. Quality assessment 
was conducted by two researchers (HN and JSC), and disagreements 
were resolved by consulting a senior researcher (MIL). 
2.5. Statistical analysis 
Separate meta-analysis by outcome of interest (prevention or man-
agement of idiosyncratic DILI and non-acetaminophen DILI-related ALF) 
and drug were conducted if data were available. Additional subgroup 
analyses were performed on RCTs sharing certain methodological fea-
tures (duration of treatment, blinding). 
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The effect size was calculated using random effects models and 
expressed by the pooled relative risk (RR) and the 95 % confidence in-
terval (CI). Heterogeneity among studies was assessed with the I2 sta-
tistic. This index ranges from 0 to 100 %, with higher values indicating 
greater heterogeneity [25]. Substantial heterogeneity was deemed if I2 
was over 50 % or p value <0.1. To further explore heterogeneity, the 
leave-one-out sensitivity analysis was conducted to test the influence of 
a single study on the overall effect size. 
Publication bias was assessed using funnel plot techniques and 
Egger’s regression test [26], as appropriate, given the limitations of 
these methods. A p value <0.1 was deemed as statistically significant. 
All analyses were carried out using STATA version 13 (Stata Corpora-
tion, College Station, TX, USA). 
3. Results 
3.1. Literature search 
A total of 2,248 studies were retrieved on the database search. Of 
them, 1,298 were duplicate records. After screening the title and ab-
stract, 924 records did not meet the inclusion criteria and were 
excluded, mainly irrelevant records to the current study or non-original 
articles, and 26 studies were reviewed. Of them, 14 records were not 
eligible and were excluded, mainly due to the lack of DILI criteria or 
relevant data, or non RCTs. After reviewing the references of the 
included studies and reviews and meta-analysis identified in the litera-
ture search, 10 additional studies were retrieved. Finally, 22 original 
RCTs were included (Fig. 1). 
3.2. Study characteristics and quality assessment 
Among 22 RCTs, 12 studies (n = 2,471 patients) were based on 
prevention and 10 studies in management (n = 797 patients) of DILI/ 
non-acetaminophen DILI-related ALF. Main characteristics and meth-
odologic quality assessment of each of the RCTs are summarised in 
Table 1 and Fig. 2. 
Silymarin (eight studies), bicyclol (four), MgIG (three), NAC (three), 
tiopronin (one), L-carnitine (one), and traditional Chinese medicines 
Fig. 1. Flow chart of the literature review process.  




Characteristics of randomised clinical trials included in the systematic review.  
Study ID 
(location) 
Mean age (SD) Female (%) Patients (N)a Treatment regimen 
Efficacy criteria Duration (wk) Diagnostic criteria Withdraw (N) 
Events (N) Adverse events (N) 
Exp Con Exp Con Exp Con Experimental Control Exp Con Exp Con 
Prevention of drug-induced liver injury 
Bicyclol 
Li 2014 (China) 
[27] 
69 68 35 39 147 153 Chemotherapy, 25 
mg bicyclol (t.d.s.) 
Chemotherapy Occurrence of grade I–IV 
liver injury 
NA CTCAE Version 3.0 [48] 6 25 72 NA 
Chu 2015 
(China) [28] 
18− 65b 27 24 117 114 TBT, 200 mg GA (t.d. 
s.), 25 mg bicyclol (t. 
d.s.) 
TBT, 200 mg GA (t.d. 
s.) 
Incidence of mild to 
severe DILI 
24 Diagnosis and treatment 
manual for adverse 
reactions of anti-TB drugs 
[49] 





37 (15) 29 (15) 24 26 54 62 TBT, 1,000 mg L- 
carnitine (b.d.) 
TBT, placebo (b.d.) Occurrence of anti-TB 
drug hepatotoxicity 
4 ALT or AST >3xULN 
(with symptoms) ALT or 
AST >5xULN (without 
symptoms) RUCAM 




60 (10) 60 (10) 47 47 114 102 Chemotherapy, 0.2 g 
MgIG into 250 mL 
10% GLC (o.d.) 
Chemotherapy, 1.2 g 
GSH into 250 mL 5% 
GLC (o.d.) 
DILI incidence 1 WHO Adverse Drug 
Reaction Terminology 
[50] 




75 (8) 73 (7) 50 47 28 32 TBT, 600 mg NAC (b. 
d.) 
TBT Anti-TB DILI incidence 2 ALT and/or AST 
>5xULN. 
0 0 12 NA            
TBil >1.5 mg/dl                
Elevated levels of ALT 
and/or AST with 
symptoms      
Silymarin  
Gu 2015 (China) 
[32] 
37 (14) 36 (14) 35 33 277 291 TBT, 70 mg silymarin 
(t.d.s.) 
TBT DILI incidence 8 Diagnosis and treatment 
manual for adverse 
reactions of anti-TB drugs 
[49] 
0 21 31 5 3          





56c (15− 78) 52c (21− 83) 63 57 27 28 TBT, 140 mg 
silymarin (t.d.s.) 
TBT, placebo (t.d.s.) Maximum ALT level 
within 4 weeks after 
treatment 
4 ALT >2xULN, TBil >1.5 
mg/dl, increase in ALT 
and jaundice, no other 
explanations of elevation 
of liver enzymes, and 
normalisation after 
withdrawal 
3 1 9 3 3          
Anti-TB DILI incidence        
Marjani 2016 
(Iran) [34] 
50 50 46 49 35 35 TBT, 140 mg 
silymarin (t.d.s.) 
TBT, 140 mg placebo 
(t.d.s.) 
DILI incidence 2 ALT or AST >3xULN with 
symptoms 
2 6 3 14 14          
Adverse events rate  ALT or AST >5xULN, or 
TBil >2 mg/dl      
Zhang 2016 
(China) [35] 
>12d 30 23 183 187 TBT, 200 mg 
silymarin (b.d.) 
TBT, vitamin C tablet Probable and possible 
DILI 
8 Probable DILI: ALT or 
AST >3xULN and TBil 
>2xULN 
9 1 0 69 65         
Peak AST/ALT ratio                
Maximum altered ALP or 
GGT value                
Adverse events rate        
(continued on next page) 
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Table 1 (continued ) 
Study ID 
(location) 
Mean age (SD) Female (%) Patients (N)a Treatment regimen 
Efficacy criteria Duration (wk) Diagnostic criteria Withdraw (N) 
Events (N) Adverse events (N) 
Exp Con Exp Con Exp Con Experimental Control Exp Con Exp Con 
Heo 2017 (South 
Korea) [36] 
58 (14) 59 (15) 38 31 45 58 TBT, 140 mg 
silymarin (b.d.) 
TBT, placebo (b.d.) DILI incidence 8 AST or ALT >3xULN or 
TBil >2xULN 
18 6 10 NA 
Wu 2017 (China) 
[37] 
48 (16) 45 (16) 41 41 118 114 TBT, 70 mg silymarin 
(t.d.s.) 
TBT DILI incidence 8 Guidelines for the 
management of drug- 
induced liver injury [51] 
4 3 16 7 9          
Incidence according to 
sex and age groups                 
Adverse events rate         
Tiopronin 
Li 2014 (China) 
[38] 
54 (2) 52 (2) 47 47 86 64 Chemotherapy, 200 
mg TP (o.d.), 2 days 
each 2 wk 
Chemotherapy Incidence of 
chemotherapy-induced 
hepatoxicity 
NA CTCAE Version 3.0 [48] 30 7f 18f NA          
Chemotherapy delays or 
dose reductions and 
transaminase elevations        




40 (6) 39 (6) 39 42 26 26 TBT, 50 mg bicyclol 
(t.d.s.) 
TBT, 100 mg DG (t.d. 
s.) 
Normalisation or 
improvement of liver 
biochemical parameters 
2 ALT >2xULN and normal 
TBil 
0 18 12 NA 
Wu 2017 (China) 
[40] 
24− 66b 20 19 79 78 25 mg bicyclol (t.d. 
s.) 
456 mg PPC (t.d.s.) Decrease of serum ALT 
levels 
4 RUCAM ≥6 11 45 31 2 2         
Normalisation rate of 
serum ALT at 2 and 4 wk  
ALT 2− 5xULN and TBil 
≤2xULN, liver 
biochemical 
abnormalities <3 months              
Comprehensive efficacy 




34 (14) 34 (16) 43 45 35 20 200 mg MgIG (o.d.) 200 mg TP (o.d.) Normalisation or 
improvement of liver 
biochemical parameters 
2 DDW-J >6 0 23g 8g 12 3          
Adverse events rate  ALT, AST, TBil, or ALP 
≥2xULN and TBil 
≤3xULN, liver 
biochemical 
abnormalities <3 months      
Wang 2019 
(China) [42] 
40 (15) 36 (15) 34 (12) 34 27 59 59 250 mL 5% GLC, 100 
mg MgIG, 200 mg 
simulated TP (o.d.). 
250 mL 5% GLC, 200 
mg simulated MgIG, 
200 mg of TP (o.d.) 
Rate of ALT 
normalisation at wk 4 
4 RUCAM ≥6 19 50 36 11 18    
38  56  250 mL 5% GLC, 200 
mg MgIG, 200 mg 
simulated TP (o.d.)  
Rate of ALT and AST 
normalisation  
ALT ≥2xULN and TBil 
≤3xULN, liver 
biochemical 
abnormalities <3 months  
48  13           
Changes of ALT and AST 
at wk 1, 2, 3 and 4         
Silymarin 
53e (42) 47e (41) 39 38 29 26 5 mg/kg silymarin 
(o.d.) 
1 mg FA (o.d.) Decrease/normalisation 
of liver enzymes 
4 ALT and/or AST >3xULN 
and ALP > 2xULN 
5 ALT: 1 ALT: 8 0 0 
(continued on next page) 
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Table 1 (continued ) 
Study ID 
(location) 
Mean age (SD) Female (%) Patients (N)a Treatment regimen 
Efficacy criteria Duration (wk) Diagnostic criteria Withdraw (N) 
Events (N) Adverse events (N) 
Exp Con Exp Con Exp Con Experimental Control Exp Con Exp Con 
Asgarshirazi 
2017 (Iran) 
[43]          
Decreasing trend and 
rebound elevation of 
enzymes after cessation 
of the treatment    
AST: 0 AST: 11                
ALP: 2 ALP: 2   
Marjani 2019 
(Iran) [44] 
52 (4) 57 (4) 52 56 27 27 TBT, 140 mg 
silymarin (t.d.s.) 
TBT, placebo Time of normalisation of 
liver enzymes and TBil 
2 ALT or AST >3xULN 
(with hepatotoxicity 
symptoms) 
1 9 ± 1h 8 ± 2h 3 4          
Severity, duration, 
mortality, and hospital 
stay  
AST or ALT >5x ULN or 
TBil >2 mg/dl               
Adverse events rate         
Traditional Chinese Medicines 
Zhou 2018 
(China) [45] 
42 (4) 42 (5) 42 46 50 50 400 mg TP added 
into 5% GLC solution 
(o.d.) and 10 mL 
Yinzhihuang (t.d.s.) 
400 mg TP added 
into 5% GLC solution 
(o.d.) 
Normalisation or 
improvement of liver 
biochemical parameters 
4 Guidelines for the 
management of drug- 
induced liver injury [51] 
0 28 20 6 14          
Adverse events rate        
Yuan 2019 
(China) [46] 
34 (7) 34 (7) 56 51 45 45 100 mL Xuebijing 
added into 100 mL 
saline, and 150 mg 
MgIG added into 250 
mL 5% GLC solution 
(o.d.) 
150 mg MgIG added 
into 250 mL 5% GLC 
solution (o.d.) 
Normalisation or 
improvement of liver 
biochemical parameters 
2 TBil, ALP, AST, or ALT 
≥2xULN, duration of 
abnormal liver function 
2− 12 wk. 
0 23 17 0 0          
Time to normalisation                 
Adverse events rate         
Management of DILI-related acute liver failure 
N-acetylcysteine 
Lee 2009 (USA) 
[12] 
NA NA 19 26 5% dextrose with 
NAC (150 mg/kg/h 
over 1 h, 12.5 mg/ 
kg/h for 4 h, 6.25 
mg/kg/h for 67 h) 
5% dextrose Overall survival rate at 3 
wk 
72 h INR ≥1.5 due to an illness 
of <24 wk duration 
NA 15 17 NA        
Transplant-free survival, 
transplantation rate at 3 
wk       
Nabi 2017 
(India) [47] 
NA NA 10 5 NAC (150 mg/kg 
over 1 h, 12.5 mg/ 
kg/h for 4 h, 6.25 
mg/kg/h for 67 h) 
5% dextrose infusion 
(placebo) for 72 h 
Overall survival rate 72 h INR ≥1.5, any degree of 
encephalopathy caused 
by illness of duration <8 
wk 
0 10 3 0 NA        
Safety and duration of 
hospital stay        
Exp: experimental group; Con: control group; NA: not available; wk: weeks; MgIG: Magnesium isoglycyrrhizinate; NAC: N-acetylcysteine; TBT: standard anti-tuberculosis treatment; GSH: glutathione; TP: tiopronin; FA: 
folic acid; DG: diammonium glycyrrhizinate; PPC: polyene phosphatidylcholine; GA: glucurolactone; GLC: glucose; DILI: drug-induced liver injury; ULN: upper limit of normality; INR: International normalized ratio; TB: 
tuberculosis; ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; TBil: total bilirubin; o.d.: once daily; b.d.: twice daily: t.d.s.: three times a day; CTCAE: Common Terminology 
Criteria for Adverse Events; DDW-J: Digestive Disease Week-Japan; RUCAM: Roussel Uclaf Causality Assessment Method. 
CTCAE version 3.0: ALT, AST or ALP > 2.5xULN or TBil >1.5xULN. 
Diagnosis and treatment manual for adverse reactions of anti-tuberculosis drugs: ALT >2xULN and/or TBil >2xULN. 
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Yinzhihuang (one) and Xuebijing (one) were tested in the intervention 
arm, while control arm mostly received either the standard supportive 
care (chemotherapy or anti-tuberculosis [anti-TB] treatment regimen [a 
combination of isoniazid, rifampicin, pyrazinamide, and ethambutol], 
when required), or placebo. Of note, Wang et al. [42] conducted a phase 
II trial exploring two different doses of the experimental compound 
MgIG. Both experimental groups treated with MgIG were included 
separately in our analysis. 
Most of the RCTs [27–47] were conducted in Asian countries (59 % 
in China), except for one trial of non-acetaminophen ALF conducted in 
the United States [12]. Heterogeneity was observed due to variations in 
the DILI/ALF case definitions and inclusion/exclusion criteria. Most 
studies defined DILI on a range of liver enzymes alanine aminotrans-
ferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase 
(ALP) or total bilirubin (TBil) elevations from 1.25 to 5-fold upper limit 
of normality (ULN). Two studies [37,45] defined DILI using the criteria 
of Aithal et al. [52] referred in the Chinese Guidelines for the manage-
ment of drug-induced liver injury [51], two studies [27,38] used the 
definition in the Common Terminology Criteria for Adverse Events 
(CTCAE) version 3.0 [48], another two trials [28,32] used the definition 
in the Chinese Diagnosis and treatment manual for adverse reactions of 
anti-tuberculosis drugs [49], and another trial [30] used the World 
Health Organization (WHO) Adverse Drug Reaction Terminology [50]. 
Non-acetaminophen ALF was consistently defined as international 
normalized ratio (INR) ≥1.5 and any degree of encephalopathy and 
coagulopathy. The use of liver-specific causality assessment scales was 
limited to four RCTs: Roussel Uclaf Causality Assessment Method 
(RUCAM) in three studies [29,40,42] and Digestive Disease Week-Japan 
(DDW-J) in one study [41]. Most studies included only adult population 
(≥18 years), including two studies with patients older than 60 years [27, 
31], whilst one study included only population aged less than 18 years 
[43], and other study included population aged >12 years [35]. Main 
efficacy criteria in the prevention RCTs was DILI incidence [27–32,34, 
36–38], maximum ALT, ALP or GGT level [33,35], or peak of AST/ALT 
ratio [35], and in management RCTs the 50 % decrease or normalisation 
of the liver parameters, or survival rate in DILI-related ALF patients. 
Duration of treatment ranged from 72 h to at least eight weeks. In 
addition, 15 trials reported adverse events (Table 1). 
A total of 15 (68 %) studies reported an appropriate randomisation 
method, mainly random number table [27,28,35,37,38,40,43,46] and 
block randomisation [12,29,33,34,36,45]. Only two trials [33,43] 
described opaque envelope as the allocation concealment method. Eight 
(36 %) RCTs were double-blind [12,29,33,34,36,41,42,44] and four 
were open-label studies [31,32,35,43], sample size estimation was done 
in nine (41 %) RCTs [12,29,31,33–35,41,43,44]. A total of four (18 %) 
RCTs involving 377 patients used an ITT approach to analyse their data 
[12,33,36,42]. In 13 studies, withdrawals during follow-up were re-
ported. Remarkably, only one study, Luangchosiri et al. [33] presented a 
low risk of bias in all quality domains evaluated (Fig. 3). 
Severity of DILI was assessed in five RCTs [28,30,32,33,37]. Two 
trials [28,32] used the Diagnosis and treatment manual for adverse re-
actions of anti-TB drugs [49], two trials [30,33] used the WHO Adverse 
Drug Reaction Terminology [50], and one trial [37] used the Chinese 
Guidelines for the management of DILI [51]. Only one management 
study [42] presented the odds of ALT normalisation according to the 
type of liver injury (hepatocellular, cholestatic and mixed). 
Interestingly, only four of the products tested in the RCTs included 
were authorised in the European Union, either centrally or nationally 
authorised: silymarin for treating toxic liver damage due to medicines, 
L-carnitine for preventing valproic acid hepatotoxicity, NAC for treating 
paracetamol overdoses, and tiopronin is only authorised for renal dis-
eases (cystinuria). Bicyclol, MgIG, and the traditional Chinese medicines 
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3.3. Silymarin 
Six RCTs evaluated the efficacy of silymarin in the prevention of DILI 
[32–37]. No differences in patients who received silymarin compared to 
those in the control arm were found (RR = 0.60; 95 % CI 0.29–1.27). 
However, significant heterogeneity between studies was detected (I2 =
56.4 %; p = 0.043) (Fig. 4). Findings from sensitivity analyses did not 
differ substantially. 
A subgroup analysis by weeks of treatment was conducted. Patients 
treated with silymarin for four weeks showed a significant reduction of 
DILI incidence in patients treated with anti-TB drugs (RR = 0.29; 95 % 
CI 0.09− 0.92). However, no reduced incidence was found in patients 
treated neither two nor eight weeks (RR = 0.89; 95 % CI 0.45–1.74, and 
RR = 0.89; 95 % CI 0.42–1.90, respectively). No significant heteroge-
neity was found in any of the subgroups even though DILI definition 
differed among the studies. (Supplemental Fig. 1). 
Silymarin was not effective in preventing DILI in open-/unclear blind 
trials (n = 1,170; RR = 0.51; 95 % CI 0.15–1.69) nor double-blind RCTs 
(n = 228; RR = 0.68; 95 % CI 0.18–2.57). Both groups showed signifi-
cant heterogeneity (I2 = 62.0 %; p = 0.072, and I2 = 65.4 %; p = 0.056, 
respectively), and results from sensitivity analyses did not vary 
significantly. 
An ancillary analysis of severity of liver injury was conducted. Pa-
tients treated with silymarin did not show a reduced risk of mild (RR =
0.49; 95 % CI 0.22–1.08) nor moderate liver injury (RR = 0.49; 95 % CI 
0.12–1.93). Notably, silymarin administration was effective in pre-
venting the development of severe liver injury (RR = 0.11; 95 % CI 
0.01− 0.90). No heterogeneity was found in any subgroup. 
Two RCTs assessed the efficacy of silymarin on the management of 
DILI. Marjani et al. [44] in a double-blind, placebo-controlled trial, of 54 
adult patients under anti-TB treatment who developed DILI did not find 
any effect of silymarin in reducing duration and severity of DILI or 
duration of hospitalisation. In addition, Asgarshizari et al. [43] con-
ducted an open-label trial including 55 children under antiepileptic 
treatment who had experienced DILI. Of them, 29 were treated with 5 
mg/kg of silymarin and 26 were treated with 1 mg of folic acid. 
Although both treatments were associated with a significant decrease of 
liver enzymes at the end of the study, a higher percentage of children 
who received folic acid showed normal ALT, AST and GGT values 
compared to children treated with silymarin. Unfortunately, due to the 
differences in outcome measures, findings from these two trials could 
not be combined in a quantitative analysis. 
3.4. Bicyclol 
Two RCTs tested the efficacy of bicyclol in preventing the onset of 
DILI in patients receiving chemotherapy [27] or anti-TB treatment [28]. 
Patients who received bicyclol showed a significant reduction in the risk 
of developing DILI compared to those allocated in the control arm (RR =
0.38; 95 % CI 0.27− 0.54), with no heterogeneity across studies (I2 =
0%; p = 0.545) (Fig. 4). 
Two trials evaluated the efficacy of bicyclol on the management of 
DILI. Altogether, patients with liver injury who were treated with 
bicyclol showed higher normalisation rates compared to those allocated 
in the standard supportive care arm (either diammonium glycyr-
rhizinate [39] or polyene phosphatidylcholine [40]) (RR = 0.69; 95 % CI 
0.52− 0.91), with no heterogeneity between studies (I2 = 0%; p = 0.556) 
(Fig. 5). 
3.5. Magnesium isoglycyrrhizinate 
One trial [30] tested the preventive effect of MgIG compared to 
glutathione in 216 adult patients receiving chemotherapy treatment. 
The incidence of hepatotoxicity grade I according to the WHO Adverse 
Drug Reaction Terminology [50] after one week of chemotherapy 
treatment was found significantly lower in patients who were treated 
with MgIG compared to those who received glutathione (5.3 % against 
11.8 %, respectively; p < 0.01). Indeed, differences in liver enzymes 
were significantly lower in patients allocated to the experimental arm 
compared to those in the control arm. 
Two double-blind RCTs assessed the role of MgIG in the management 
of DILI [41,42]. Patients who had DILI and were treated with MgIG 
showed significantly greater ALT normalisation rates compared to those 
allocated in the control group who received tiopronin (RR = 0.40, 95 % 
CI 0.27− 0.60), with no heterogeneity across studies (I2 = 0%; p =
0.925) (Fig. 5). 
3.6. N-Acetylcysteine 
In an open-label trial conducted in 60 patients aged 60 and over, 
Baniasadi et al. [31] studied the efficacy of NAC on the prevention of 
anti-TB DILI. Among 28 patients who received standard anti-TB treat-
ment combined with 600 mg of NAC, none of them developed DILI after 
two weeks of follow-up. In contrast, among 32 patients who only 
received standard anti-TB treatment, 12 of them (37.5 %) experienced 
DILI within two weeks of follow-up. 
On the other hand, two RCTs assessed the role of NAC in survival of 
Fig. 2. Individual risk of bias assessment of included randomised clinical trials.  
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Fig. 3. Risk of bias presented as percentages across the included randomised clinical trials.  
Table 2 
Summary of product characteristics of agents used in clinical trials in DILI and authorisation status within the European Union countries.  






Labelled indications Authorised 
pharmaceutical 
forms 
A05B Silymarin (Silybum 
marianum (L.) Gaertn., 
fructus) 
Antioxidative, antifibrotic, anti- 
inflammatory, protein synthesis 
stimulating and membrane 
protecting mechanisms 
Yes NA Toxic liver damage, e.g. due to 
alcohol, medicines, or due to 
metabolic dysfunctions like diabetes; 
supportive treatment of chronic 
inflammatory liver diseases and 
cirrhosis of the liver 
Capsules or 
tablets 
NA Bicyclolb Effect of scavenging free radicals 
and protecting liver cell 
membranes; protection of liver cell 
nuclear DNA from damage and 
reduction of the occurrence of cell 
apoptosis 
No No Treatment of elevated 
aminotransferase caused by chronic 
hepatitis 
Tablets 
A16AA01 L-carnitinea Favor the metabolic flow in the 
Krebs cycle, with the same 
mechanism with which stimulates 
the activity of pyruvate 
dehydrogenase and, in skeletal 
muscle, the oxidation of branched 
fatty acids 
No Yes Treatment of primary and secondary 
L-carnitine deficiencies; treatment of 
hyperammonemic encephalopathy 
and/or hepatotoxicity due to valproic 
acid overdose/toxicity; prophylactic 
treatment in patients receiving 
valproic acid who are at increased risk 
of hepatotoxicity; treatment of 
secondary L-carnitine deficiency in 





Prevention of the increase of serum 
transaminase, reduction of 
hepatocyte degeneration, necrosis, 
and inflammatory cell infiltration 
No No Chronic viral hepatitis and acute drug- 
induced liver injury 
Injection 
R05CB01 N-acetylcysteinea Cytoprotective activity in the 
respiratory system against 
damaging action of oxidative stress 
by oxidative free radicals 
No Yes Adjunctive treatment in respiratory 
processes that occur with excessive or 
thick mucous hypersecretion; 
treatment of paracetamol overdoses 
Tablets or 
injection 
G04BX16 Tioproninc Reduction of soluble cystine by the 
formation of a water-soluble mixed 
disulfide as a result of a thiol- 
disulfide exchange with cystine 
No Yes Prevention of cystine stone formation 
in adults and pediatric patients 20 kg 
and greater with severe homozygous 
cystinuria 
Tablets 
NA Xuebijingb NA No No Removal of blood stasis and 
detoxification; fever, wheezing, 
palpitations, irritability, and other 
syndromes of blood stasis and poison; 
treatment of systemic inflammatory 
response syndrome induced by 
infection 
Injection 
NA Yinzhihuangb NA No No Acute, persistent, chronic hepatitis 
and severe hepatitis (type I) caused by 
damp-heat toxins, and other types of 
severe hepatitis 
Oral liquid  
a Information retrieved from the Spanish Medicines Agency. 
b Drug authorised in China. Information retrieved from the summary of product characteristics. 
c Information retrieved from the French Medicines Agency. 
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adult patients with idiosyncratic drug-induced ALF [12,47]. The use of 
NAC in these patients (n = 60) did not show improvements in overall 
survival rates (RR = 0.44; 95 % CI 0.11–1.68), with low heterogeneity 
across studies (I2 = 20.4 %; p = 0.262) (Fig. 5). 
3.7. Tiopronin 
Li and colleagues [38] performed a trial to evaluate the efficacy of 
tiopronin in chemotherapy-induced hepatotoxicity. They reported a 
significant lower incidence of chemotherapy-induced liver injury in 86 
patients whose treatment was supplemented with 200 mg of tiopronin 
(abnormal [>2.5xULN] ALT, AST and TBil rates were 8.3 %, 7.8 % and 
6.7 %, respectively) compared to 64 patients who received standard 
chemotherapy treatment alone, with frequencies of abnormal ALT, AST 
and TBil values of 29 %, 26 % and 31 %, respectively (RR = 0.29; 95 % 
CI 0.13− 0.65) (Fig. 4). 
3.8. L-Carnitine 
An Iranian double-blind trial [29] aimed to evaluate the efficacy of 
oral L-carnitine in preventing anti-TB DILI. After four weeks of treat-
ment, among 54 patients who received standard anti-TB treatment 
supplemented with 2,000 mg of oral carnitine solution daily, nine pa-
tients (17 %) developed DILI, while 20 of 62 patients (32 %) who only 
received standard anti-TB treatment experienced DILI (p = 0.049). 
Fig. 4. Pooled efficacy of pharmacological/herbal agents in randomised clinical trials in drug-induced liver injury prevention. 
* Efficacy is measured as preventing elevated ALT levels. 
Fig. 5. Pooled efficacy of pharmacological/herbal agents in randomised clinical trials in drug-induced liver injury management. 
* Efficacy is measured as ALT normalisation; ^ Paediatric population. 
(a) 100 mg per day of magnesium isoglycyrrhizinate; (b) 200 mg per day of magnesium isoglycyrrhizinate. 
Marjani et al. [44] used as efficacy criteria the time of normalisation of liver enzymes. 
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3.9. Traditional Chinese medicines 
Two trials reported the efficacy of traditional Chinese medicines 
combined with other drugs in the treatment of DILI. Zhou [45] reported 
that among 50 patients with DILI (defined according to Aithal et al. 
[52]) who were treated with tiopronin combined with Yinzhihuang 
(composed of Herba artemisiae scopariae [Yin Chen], Gardenia [Zhi Zi], 
honeysuckle [Jin Yin Hua], and Scutellaria [Huang Qin]), in 46 of them 
(92 %) liver parameters tended to normalisation, compared to 36 (72 %) 
who received only tiopronin (p < 0.05). Moreover, Yuan et al. [46] 
reported that 45 DILI cases (defined as ALT, AST, ALP or TBil ≥2xULN) 
who received a combined treatment of MgIG and Xuebijing (composed 
of Angelica sinensis [Dang Gui], Salvia miltiorrhiza [Dan Shen], Ligusticum 
chuanxiong [Chuan Xiong], Radix Paeoniae Rubra [Chi Shao], and saf-
flower [Hong Hua]) showed higher liver indices improvement or nor-
malisation rates (39 patients, 87 %) compared to 31 out of 45 cases (69 
%) who were treated only with MgIG (p < 0.05). However, neither 
Yinzhihuang (RR = 0.73; 95 % CI 0.50–1.08) nor Xuebijing adminis-
tration (RR = 0.79; 95 % CI 0.54–1.14) was effective when the outcome 
was restricted to normalisation of liver parameters (Fig. 5). 
3.10. Adverse effects 
An analysis to study the adverse effects rate of drugs used in the 
prevention and management of DILI was performed. The most frequent 
reported adverse reactions of silymarin were nausea, anorexia, and 
abdominal pain. The reported adverse reactions of bicyclol comprised 
dizziness, headache, abdominal distension, and mild diarrhoea. The 
main adverse reactions associated to MgIG were granulocytopenia, fever 
and nausea. Adverse effects related to NAC treatment were nausea and 
vomiting. Of note, eight studies (bicyclol [two], MgIG [one], NAC 
[three], silymarin [one], tiopronin [one]) did not provide complete in-
formation of adverse events (Table 1). 
Patients who were treated with silymarin for either preventing or 
treating DILI, compared to those who received placebo or standard 
supportive care, did not show a higher risk of adverse events (RR = 1.05; 
95 % CI 0.84–1.32). Likewise, neither patients who received bicyclol 
(RR = 1.17, 95 % CI 0.36–3.79) nor MgIG (RR = 0.88; 95 % CI 
0.47–1.63) were at increased risk for presenting adverse events. No 
substantial heterogeneity was detected. Therefore, these drugs showed a 
safe profile (Fig. 6). 
3.11. Publication bias 
Despite the few number of studies available, no publication bias was 
(cautiously) suggested on regard of RCTs which used silymarin on the 
prevention of DILI (p = 0.825), nor those trials which assessed the ef-
ficacy of MgIG on the management of DILI (p = 0.991) (Supplemental 
Fig. 2). Unfortunately, publication bias could not be evaluated for the 
remaining pharmacological or herbal agents due to the low number of 
studies available. 
4. Discussion 
In recent years, prevention and management of DILI have received 
growing attention due to its increasing public health burden [2]. To our 
knowledge, this is the first systematic review that summarises the 
findings of RCTs aimed to prevent idiosyncratic DILI and manage the 
development of ALF in DILI. This review emphasises the lack of stand-
ardised diagnostic criteria of DILI, as well as differences in design and 
methodology of the RCTs analysed. 
Several agents with presumed beneficial effects on DILI have been 
tested in RCTs in the past years, especially in Eastern countries, probably 
due to the higher prevalence of DILI caused by anti-TB agents compared 
to Western countries [53]. Silymarin has been the most commonly 
evaluated agent in clinical trials. Several mechanisms underlying the 
hepatoprotective effect of silymarin have been described, including its 
antioxidant activity in the liver and its inhibitor role of several isoforms 
of hepatic cytochrome P450 2E1 induced by anti-TB drugs [54,55]. In 
addition, a recent review concluded that silymarin was a well-tolerated 
agent that can be used as a supportive treatment in most forms of liver 
disease [56]. 
Our analysis showed no overall apparent beneficial effect of sily-
marin on DILI prevention. When stratified analyses by treatment dura-
tion were performed, silymarin exerted a hepatoprotective effect on 
anti-TB DILI incidence only when patients were treated for four 
weeks. Though prior studies demonstrated that the development of 
clinical symptoms in anti-TB hepatotoxicity had a wide time span, 
ranging from six weeks to six months [57], other authors reported that 
nearly 70 % of patients developed anti-TB hepatotoxicity within 30 
days, and 88 % within eight weeks [58,59]. Nonetheless, the results of 
this post hoc analysis should be interpreted carefully to avoid misleading 
conclusions. Due to the variability in the trial duration and availability 
of data, each subgroup included different trials. Consequently, the 
capability to detect estimated effects varied, and may explain these 
findings. Interestingly, in a recent meta-analysis of silymarin RCTs 
stratified to treatment duration, the authors also faced the same meth-
odological shortcoming [60]. 
Nevertheless, as reported in prior systematic reviews, findings from 
low methodological quality trials (open-/unclear blinded) tended to 
exaggerate the benefits of silymarin treatment when compared to 
double-blind trials [61]. 
The Chinese Society of Hepatology Guidelines suggests that sily-
marin may be used to treat mild liver inflammation [62]. However, only 
three RCTs reported DILI according to its severity, and two of them were 
open-/unclear blinded trials, which may limit the validity of these 
findings. Nonetheless, findings reported by Luangchoshiri et al. [33] in a 
high-quality trial are in line with Chinese Society of Hepatology 
Guidelines, although the small sample size would have limited the sta-
tistical power of their analyses. 
In addition, DILI patients treated with silymarin did not show clinical 
improvements in the two management RCTs analysed [43,44]. None-
theless, the low number of patients should be taken into account as a 
limitation that may have underpowered the analysis, which precludes to 
detect differences between the groups of treatment. 
Previous investigations have reported a hepatoprotective effect of 
bicyclol on DILI in mice, treated with up to 200 mg/kg of the compound, 
mediated by its antioxidant and anti-inflammatory properties [63–66]. 
However, evidence for the efficacy in the treatment of DILI in humans is 
still scarce. In a Chinese pharmacoeconomic study using a decision tree 
analysis approach to evaluate four hepatoprotective drugs (bicyclol, 
tiopronin, reduced glutathione and diammonium glycyrrhizinate) for 
the treatment of DILI, authors concluded that bicyclol showed the 
greatest efficacy and safety, as well as the lower incremental 
cost-effectiveness ratio [67]. However, the fact that all trials were con-
ducted in China do not permit generalisability of these findings. 
The analysis of four trials in the current study showed that admin-
istration of bicyclol was related to a reduced incidence of DILI and 
higher normalisation rates. It should be noted that the two trials 
assessing the role of bicyclol in DILI prevention diverged in the DILI 
definition and the eligible population. Indeed, the threshold in amino-
transferases >2.5xULN to define DILI are lower to those recommended 
in Clinical Practice Guidelines [2,62,68], and may be misleading. 
Further, one of these trials [28] evaluated the efficacy of bicyclol in 
conjunction with glucurolactone, used in prevention of anti-TB DILI in 
China, compared to the control group who received glucurolactone, 
which may have distorted the findings. In addition, there were differ-
ences regarding the DILI criteria, doses administered and the control 
group in the two DILI management trials. Given the low number of trials, 
the lack of information about its methodological design (i.e. allocation 
concealment and blinding), and the aforementioned limitations, find-
ings should be interpreted cautiously. 
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MgIG is used in China as an anti-inflammatory and hepatoprotective 
agent in the treatment of inflammatory liver diseases [22,69]. Though 
the exact mechanisms in human remain to be elucidated, some studies in 
animal models have proposed that 9–50 mg/kg of MgIG hep-
atoprotective effects may be correlated with an attenuation of oxidative 
stress [70,71]. Despite an apparent reduced incidence of DILI and 
greater ALT normalisation rates in patients treated with parenteral 
MgIG, our findings were based on three trials with poor description of 
methodological design, low stringent DILI diagnostic criteria, short-term 
follow-up, and lack of clinically meaningful endpoints. Therefore, the 
validity of these results is compromised and should be interpreted 
cautiously. 
Despite there being no specific treatment for DILI-related ALF, with 
the exception of liver transplantation, NAC has been tried in idiosyn-
cratic drug-related ALF given its efficacy and good safety profile in 
acetaminophen-induced ALF. Hu et al. [72] in a meta-analysis of clinical 
studies, concluded that NAC treatment improved transplant-free sur-
vival and survival after transplantation, but not overall survival in pa-
tients with non-acetaminophen-induced ALF. Although case reports 
have supported the use of NAC in drug-induced ALF [73], findings from 
a systematic review were inconclusive due to the low available evidence 
[74]. In the present study, restricting the study population to idiosyn-
cratic drug-induced ALF patients, no improvements in overall survival in 
patients treated with NAC were found. It should be noted that, based on 
the limited number of trials and the lack of data of drug-induced ALF 
patients in RCTs, these findings may be underpowered. Since drugs are a 
main cause of ALF [1,75], and NAC is the most cogent drug in treating 
acetaminophen overdose, there is a need of high quality RCTs to validate 
the efficacy of NAC in preventing and treating non-acetaminophen 
DILI-related ALF. 
Although corticosteroids have been suggested in the management of 
some forms of DILI, no RCTs using these agents were identified. 
Noticeably, a recent systematic review focused on the management of 
immune-mediated hepatotoxicity pointed out the possibility of avoiding 
corticosteroids treatment in patients with immune-related hepatitis due 
to immune checkpoints inhibitors [76]. Therefore, to what extent the 
use of corticosteroids in the management of DILI would be useful remain 
to be elucidated. 
The need of high-quality clinical trials to enhance the prevention and 
management of DILI has been underscored in the past years [77]. 
Several differences in trial design were identified across the RCTs 
included. Prior investigations on the influence of study design charac-
teristics on intervention effects concluded that bias derived from an 
inadequate or unclear sequence generation or allocation concealment, 
and the lack of a double-blind design, may exaggerate the estimates of 
intervention effects, especially in trials which assessed subjective out-
comes [78,79]. Although the outcomes measured in the included RCTs 
were evaluated objectively (based on established laboratory parame-
ters), the small sample sizes limited the number of robust endpoints such 
as ALF, transplantation, or death. Therefore, effects are likely to be 
over-estimated due to selection bias. 
Another critical concern identified throughout this systematic review 
is the heterogeneity in DILI case qualification. DILI criteria ranged from 
a 1.25-fold elevation the ULN of liver biochemistries to a threshold of 5 
times the ULN. This lack of harmonisation in criteria makes the com-
parison between studies extremely difficult. Besides, minor elevation in 
transaminases qualified as DILI might, indeed, represent adaptive, non- 
progressive changes rather than true hepatotoxicity. The differences 
observed in clinically not robust primary efficacy estimates, jointly with 
the aforementioned variability in DILI case qualification criteria, the 
need to properly characterise the underlying condition and stage of 
disease for enrolment [80], underscores the need of reaching an inter-
national consensus in the context of future clinical trials to standardise 
DILI case qualification, severity index criteria, and endpoints to evaluate 
the efficacy of novel interventions for exploring novel biomarkers in 
DILI. 
Moreover, due to the lack of specific diagnostic tests and biomarkers, 
causality assessment of DILI relies on subjective expert consensus 
opinion. The use of the RUCAM scale as a validated liver-specific scale 
should be a valid instrument in causality assessment of DILI [81,82]. 
This study has several strengths. This is the first attempt to perform a 
systematic review of clinical trials designed for prevention and man-
agement of idiosyncratic DILI. Further, we performed an extensive 
literature search in six different databases. Nonetheless, an inherent 
weakness is the inability of including unfinished or unpublished trials. 
However, to overcome this limitation, we performed a search in grey 
Fig. 6. Pooled effects of adverse events of pharmacological/herbal agents tested in randomised clinical trials in drug-induced liver injury prevention/management. 
Eight trials did not provide complete information of adverse events. 
(a) 100 mg per day of magnesium isoglycyrrhizinate; (b) 200 mg per day of magnesium isoglycyrrhizinate. 
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literature to identify these trials. Another limitation is that, despite our 
complete search, our quantitative analyses are underpowered due to the 
scarcity of clinical trials. Further, some of the trials included, due to its 
methodological design and quality, would have exaggerated interven-
tion effects [24] and consequently our findings should be interpreted 
cautiously. 
5. Conclusions 
This systematic review illustrates the difficulties and deficiencies of 
clinical research on DILI, due to the rarity of the condition and hetero-
geneity of the manifestations, which have led some authors to consider 
that RCTs for DILI are too challenging and often inconclusive. In addi-
tion, due to its low frequency, investment in preventing DILI is hard to 
justify. A risk-benefit analysis would tend to discount prophylaxis due to 
questions around cost effectiveness and safety, except for patients un-
dergoing anti-TB or anti-cancer therapy in addition to other vulnerable 
populations. There is a need for planning and execution of coordinated 
multicentre clinical trials in DILI aimed at investigating the effectiveness 
of known and novel interventions that could improve clinical outcomes 
of DILI within the framework of adaptive clinical trial design. These 
trials would need to define threshold criteria for patient inclusion and 
sample sizes to ensure adequate statistical power, together with moni-
toring plans, stopping criteria and precisely-defined endpoints. 
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